Dysfunction of the PI3 kinase/Rap1/integrin αIIbβ3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia-Reference-Cited by-同舟云学术

Dysfunction of the PI3 kinase/Rap1/integrin αIIbβ3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia

Published:2013-02-14 Issue:7 Volume:121 Page:1209-1219
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Moore Samantha F.¹,Hunter Roger W.¹,Harper Matthew T.¹,Savage Joshua S.¹,Siddiq Samreen²,Westbury Sarah K.²,Poole Alastair W.¹,Mumford Andrew D.²,Hers Ingeborg¹

Affiliation:

1. School of Physiology and Pharmacology, School of Medical Sciences, and

2. Bristol Heart Institute, University of Bristol, Bristol, United Kingdom

Abstract

Key PointsPlatelets from essential thrombocythemia patients have an intrinsic impairment in the P13kinase/Rap1/integrin αIIbβ3 signaling pathway. This explains the clinical observation that in vitro platelet aggregation is impaired in patients with essential thrombocythemia.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/7/1209/1367787/zh800713001209.pdf

Reference50 articles.

1. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.;Tefferi;Blood,2007

2. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.;Elliott;Br J Haematol,2005

3. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.;Tefferi;Semin Thromb Hemost,2007

4. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.;Vannucchi;Intern Emerg Med,2010

5. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.;Finazzi;Leukemia,2012

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet proteomic profiling reveals potential mediators of immunothrombosis and proteostasis in myeloproliferative neoplasms;Blood Advances;2024-08-14

2. Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications—A Narrative Review;Current Issues in Molecular Biology;2024-08-02

3. Immunological role of Gas6/TAM signaling in hemostasis and thrombosis;Thrombosis Research;2024-06

4. Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms;2023-10-25

5. Thrombosis and Myeloproliferative Neoplasms;Pathogenesis and Treatment of Leukemia;2023